A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Launched by HOFFMANN-LA ROCHE · Jul 16, 2008
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>=18 years of age;
- • locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV);
- • eligible to start treatment with Tarceva, or receiving Tarceva for \<=5 days.
- Exclusion Criteria:
- • presence of skin rash or other signs of skin toxicity;
- • treatment with any systemic or intranasal antibiotic within 7 days before randomization;
- • treatment with other topical formulation within 14 days before randomization;
- • other anticancer therapy in addition to Tarceva.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rio De Janeiro, Rj, Brazil
Ijui, Rs, Brazil
Ribeirao Preto, Sp, Brazil
Taguatinga, Df, Brazil
Natal, Rn, Brazil
Itajai, Sc, Brazil
Sao Paulo, Sp, Brazil
Goiania, Go, Brazil
Porto Alegre, Rs, Brazil
Salvador, Ba, Brazil
Fortaleza, Ce, Brazil
Belo Horizonte, Mg, Brazil
Divinopolis, Mg, Brazil
Recife, Pe, Brazil
Curitiba, Pr, Brazil
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials